Detalhe da pesquisa
1.
The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis.
Eur J Neurol
; 30(10): 3212-3220, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37337838
2.
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Circulation
; 144(16): 1295-1307, 2021 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34459214
3.
Highly effective disease-modifying treatment as initial MS therapy.
Curr Opin Neurol
; 34(3): 286-294, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33840776
4.
Editorial: Challenges in the diagnosis and treatment of multiple sclerosis.
Curr Opin Neurol
; 34(3): 275-276, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33935216
5.
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.
Mult Scler
; 21(3): 282-93, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25533299
6.
Prediction of antibody persistency from antibody titres to natalizumab.
Mult Scler
; 18(10): 1493-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22454098
7.
Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis.
J Clin Med
; 11(23)2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36498739
8.
Demyelination versus remyelination in progressive multiple sclerosis.
Brain
; 133(10): 2983-98, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20855416
9.
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.
Asian J Urol
; 7(3): 301-308, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32742930
10.
The SH2D2A gene and susceptibility to multiple sclerosis.
J Neuroimmunol
; 197(2): 152-8, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18554728
11.
Smoking affects the interferon beta treatment response in multiple sclerosis.
Neurology
; 90(7): e593-e600, 2018 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29343473
12.
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology
; 90(20): e1805-e1814, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695594
13.
Widespread demyelination in the cerebellar cortex in multiple sclerosis.
Brain Pathol
; 17(1): 38-44, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17493036
14.
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
Neurol Genet
; 2(4): e87, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27540591
15.
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
Lancet
; 364(9440): 1149-56, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15451222
16.
Endogenous interferon-ß-inducible gene expression and interferon-ß-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.
PLoS One
; 10(3): e0118830, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25738751
17.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Neurology
; 82(7): 573-81, 2014 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24453078
18.
Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
Neurology
; 82(17): 1499-507, 2014 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24682973
19.
Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
PLoS One
; 9(4): e95540, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24748023
20.
Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
Expert Rev Neurother
; 13(12): 1309-17, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24236901